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Abstract
We report on a 394delTT homozygous cystic fibrosis (CF) patient with severe disease progression. At the diagnosis made at
the age of 2.5 months, he suffered from macrocytic anaemia as the most prominent symptom of CF, malnutrition, hypoproteinaemia
and profound hypoalbuminaemia, but demonstrated only minimal pulmonary symptoms. Abnormal sweat chlorides confirmed the
diagnosis of CF. Severe pulmonary and liver disease caused death after 6 years.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
In most patients with cystic fibrosis (CF), pulmonary
symptoms initially prevail w1x. Another predominant
feature is maldigestion that frequently begins in early
childhood. Pancreatic exocrine dysfunction causes mal-
digestion characterised by failure to thrive, diarrhoea,
hypoproteinaemia, oedema and anaemia. Severe anaemia
as the initial manifestation was described rarely w2,3x.
Prospectively, the frequency of clinically significant
anaemia has been estimated to develop in 4% of CF
infants w4x.
The frameshift mutation 394delTT, which is very rare
among CF chromosomes worldwide, was found to be a
relatively common cause of CF in Northern European
countries w5–7x. In Estonia, this mutation ranks as the
second most common CF alteration, accounting for
13.3% of CF chromosomes w8x.
We describe a male patient with severe anaemia at
diagnosis, who developed chronic pulmonary disease at
1 year of age, liver cirrhosis at the age of 4 years and
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despite aggressive treatment died of cardiopulmonary
deficiency at the age of 6 years.
2. Case report
A 1-month-old entirely breastfed boy was admitted to
the local hospital due to failure to thrive and frequent
dark green stools. He was born at term with a birth
weight of 3000 g. Weight at hospitalisation was 2900 g.
His hemogram was normal (haemoglobin 140 gyl, red
blood cells (RBC) 4.4=10 ). Due to probable maldi-12
gestion (loose stools with undigested food particles),
the infant was treated for 10 days with pancreatic
enzyme supplements. Formula milk was added to his
diet. He gained 250 g in 10 days and was discharged.
Further weight gain remained poor, and at the age of
2.5 months he was readmitted with malnutrition (weight
3430 g y4 S.D., length 55 cm y2.5 S.D.) and severe
anaemia (haemoglobin 65 gyl, RBC 1.74=10 yl,12
hematocrit 0.22), initially to the local hospital and then
to the University Hospital due to persistent anaemia.
The routine laboratory workup demonstrated anisopoik-
ilocytosis and polychromasia in the peripheral blood
smear; macrocytoses with mean corpuscular volume 126
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fl, (normal 84–105 fl), mean corpuscular haemoglobin
37 pg (normal 27–34 pg), reticulocytes 3.1%, throm-
bocytopaenia 99=10 . Serum total protein and albumin9
concentrations were low, 40 gyl and 23 gyl, respectively.
Unconjugated bilirubin, serum iron, an indirect and
direct Coombs test, a Price–Jones curve and bone
marrow smear were all normal. The patient has neither
hepato–or splenomegaly nor other signs of hemolysis.
He had not passed any visible blood, and several tests
for faecal haemoglobin were negative. Nevertheless, the
mother reported an infrequent cough and a salty-tasting
kiss. The chest radiograph demonstrated minimal chang-
es with left-side lobular overaeration, but no sign of
pneumonia. Abnormal sweat chlorides (105–119 mmoly
l) confirmed the diagnosis of CF.
The infant was treated with albumin and glucose
infusions, antibiotics, pancreatic enzymes and water-
soluble vitamins (C, B , B and folate). As anaemia12 6
continued, he was transfused with packed red blood
cells. After confirmation of the CF diagnosis, liposoluble
vitamins A (4000 IUyday), D (500 IUyday) and E (6
mgyday) were added. The patient was discharged after
20 days with a weight of 3850 g and normalised blood
count (haemoglobin 122 gyl, RBC 3.6=10 )12
The infant later showed severe disease manifestation,
and was readmitted at the age of 4 months with bilateral
pneumonia (Staphylococcus aureus). Altogether, during
the first year of life he was hospitalised in the CF
Centre seven times due to pulmonary exacerbations. His
weight gain was still poor, although dietary intake was
calculated at between 130–150% of the required values
for his age.
The illness progressed rapidly. The first Pseudomonas
aeruginosa positive sputum was found at 6 months of
age, and chronic colonisation developed approximately
1 year later. Chronic pulmonary disease with left-side
atelectasis and persistent diffuse changes characteristic
of CF were diagnosed from 10 months of age, and
severe cardiopulmonary deficiency at 2 years 9 months.
Liver disease developed quickly. Liver enzymes
increased significantly after 3 years of age, and by the
age of 4.5 years liver cirrhosis with signs of portal
hypertension developed. Although the patient was hos-
pitalised 21 times at the CF centre, mostly due to
pulmonary exacerbations, the boy died at the age of 6
years.
Molecular analysis of the CFTR gene revealed muta-
tion 394delTT in both alleles. His parents were of
Estonian ancestry and were non-consanguinous over at
least five generations. Haplotype analysis was performed
using two extragenic (XV2c, KM19) and four intragenic
polymorphic sites (IVS8CA,IVS17BTA, IVS17BCA,
IVS5Ty7Ty9T) w8x and interestingly, different haploty-
pes were found. Paternal mutation has been linked with
microsatellite haplotype By23y36y13-9T, exclusively
associated with the 394delTT mutation in Finland w5x,
and the maternal alteration has been connected with the
By25y36y13-9T haplotype found only in the Estonian
population.
3. Discussion
In this anaemia patient, malnutrition and hypoalbu-
minemia were the most prominent symptoms, when CF
was diagnosed at the age of 2.5 months. Overall, the
pathogenesis of early anaemia in CF has not been
conclusively established. Most previous studies describe
the anaemia as haemolytic, implicating the malabsorp-
tion of fat-soluble vitamin E w4,9–11x, which appears
to act as a protective antioxidant toward peroxidation of
membranous polyunsaturated fatty acids w12x. It has also
been shown, however, that vitamin E deficiency in CF
patients is irrespective of pancreatic function, body
weight, and even the administration of pancreatic
enzymes and liposoluble vitamins w13x. Among infants
newly diagnosed with CF, the frequency of vitamin E
deficiency has been found to be very high, ranging from
38 to 59% w14,15x. Interestingly, only approximately 4%
of these children develop clinically significant anaemia
w3,4x, suggesting that additionalymodifying factors most
likely contribute to the manifestation of severe anaemia
in CF patients. Although in our patient, the only inti-
mation of haemolysis was mild reticulocytosis and other
features did not contribute to typical haemolytic anae-
mia, due to lack of the data we could not rule out the
importance of vitamin E deficiency in the initiation of
anaemia. Although after the diagnosis of CF, vitamin E
was supplemented in low levels according to present
guidelines, signs of haemolytic anaemia did not reoccur.
The slightly hypercromic macrocytosis detected is
harder to explain. One reason could be a deficiency of
folic acid due to malabsorption, or increased folate
utilisation by rapidly-proliferating bone marrow in
chronic haemolytic anaemia, or a combination of both.
Although anaemia in our patient was not prolonged,
persistent malnutrition plausibly contributed to the man-
ifestation of anaemia.
Our 394delTT homozygous patient showed extraor-
dinarily complicated disease manifestation, although CF
was diagnosed at an early age and aggressive treatment
was provided at the CF Centre. This finding correspond-
ed with the severe disease manifestation with high sweat
chlorides, pancreatic insufficiency, and high rate of liver
disease described in a group of Swedish 394delTT
patients w7x.
The severe manifestation of the disease correlates
with the prediction from the character of the mutation.
Due to the deletion in exon 3, stopcodon is generated
in exon 4 and truncated protein is synthesised. In
consequence, no functional CFTR protein is expected at
the apical membrane of the epithelial cells in patients
homozygous for the 394delTT mutation w16x. In a recent
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study, no CFTR activity could be demonstrated with
nasal epithelial cells derived from 394delTTyF508del
compound heterozygous patients w17x.
4. Conclusion
According to the predicted molecular character of
394delTT mutation, our homozygous patient showed
severe disease manifestation. In rare cases of CF, anae-
mia may be the leading symptom present together with
malnutrition, and should always be considered in the
differential diagnosis of anaemia. More investigations
are needed to clarify the mechanisms of early anaemia
in CF and to assess the possible poor prognostic value
of clinically significant anaemia in CF babies.
Acknowledgments
This study was supported by ESF grant 4578 and
Estonian Ministry of Education target-financed project
0180518s98.
References
w1x Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a
consensus statement. Cystic fibrosis foundation consensus pan-
el. J Pediatr 1998;132(4):589–95.
w2x Dolan TE. Haemolytic anemia and edema as the initial signs
in infants with cystic fibrosis. Clin Pediatr 1976;59:533–42.
w3x Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G,
Heijerman HGM, et al. Nutrition in patients with cystic fibrosis:
a European consensus. J Cystic Fibrosis 2002;1:51–75.
w4x Wilfond BS, Farrell PM, Laxova A. Severe haemolytic anemia
associated with vitamine E deficiency in infants with cystic
fibrosis. Clin Pediatr 1994;33:2–7.
w5x Kere J, Estivill X, Chillon M, Morral N, Nunes V, Norio R, et
al. Cystic fibrosis in a low-incidence population: two major
mutations in Finland. Hum Genet 1994;93:162–6.
w6x Estivill X, Bancells C, Ramos C, Biomed CF. Mutation analysis
consortium. Geographic distribution and regional origin of 272
cystic fibrosis mutations in European populations. Hum Mutat
1997;10:135–54.
w7x Strandvik B, Bjorck E, Fallstrom M, Gronowitz E, Thountzour-¨ ¨
is J, Lindblad A, et al. Spectrum of mutations in the CFTR
gene of patients with classical and atypical forms of cystic
fibrosis from southwestern Sweden: identification of 12 novel
mutations. Genet Test 2001;5:235–42.
w8x Teder M, Klaassen T, Oitmaa E, Kaasik K, Metspalu A.
Distribution of CFTR gene mutations in cystic fibrosis patients
from Estonia. J Med Genet 2000;37(8):16.
w9x Farrell PM, Bieri JG, Fratantoni JF, Wood RE, di Sant’Agnese
PA. The occurrence and effects of human vitamin E deficiency.
A study in patients with cystic fibrosis. J Clin Invest
1977;60:233–41.
w10x Sasavan S, Bhambhani K, Abdulhamid I, Ravindranath Y.
Cystic fibrosis and anaemia in infancy. Lancet 1997;350:295.
w11x Swann IL, Kendra JR. Anaemia, vitamin E deficiency and
failure to thrive in an infant. ClinLab Haematol Feb
1998;20(1):61–3.
w12x Winklhofer-Roob BM, Ziouzenkova O, Puhl H, Ellemunter H,
Greiner P, Muller G, et al. Impaired resistance to oxidation of
low density lipoprotein in cystic fibrosis: improvement during
vitamin E supplementation. Free Radic Biol Med.
1995;19:725–33.
w13x Lancellotti L, D’Orazio C, Mastella G, Mazzi G, Lippi U.
Deficiency of vitamins E and A in cystic fibrosis is independent
of pancreatic function and current enzyme and vitamin supple-
mentation. Eur J Pediatr 1996;155(4):281–5.
w14x Sokol RJ, Reardon MC, Accurso FJ, Stall C, Narkewicz M,
Abman SH, et al. Fat-soluble-vitamin status during the first
year of life in infants with cystic fibrosis identified by screening
of newborns. Am J Clin Nutr 1989;50:1064–71.
w15x Marcus MS, Sondel SA, Farrell PM, Laxova A, Carey PM,
Langhough R, et al. Nutritional status of infants with cystic
fibrosis associated with early diagnosis and intervention. Am
J Clin Nutr 1991;54:578–85.
w16x Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride
channel dysfunction in cystic fibrosis. Cell 1993;73(7):1251–
4 (Jul 2).
w17x Andersson C, Dragomir A, Hjelte L, Roomans GM. Cystic
fibrosis transmembrane conductance regulator (CFTR) activity
in nasal epithelial cells from cystic fibrosis patients with severe
genotypes. Clin Sci 2002;103:417–24.
